These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38127586)

  • 41. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
    Ebbert PT; Xavier F; Seaman CD; Ragni MV
    Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data.
    Cho H; Yoo KY; Shin JY; Lee EK; Choi B
    J Thromb Haemost; 2024 Jun; 22(6):1640-1648. PubMed ID: 38395359
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of prophylaxis with emicizumab in hemophilia A: A study of 13 patients.
    Ocaña Gómez MÁ; Ferrer Machín A; Vera Cabrera M; Álvarez Tosco KI; Ríos de Paz M; de Dios García MD
    Med Clin (Barc); 2024 Feb; 162(3):134-137. PubMed ID: 37599198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low immunogenicity of emicizumab in persons with haemophilia A.
    Schmitt C; Emrich T; Chebon S; Fernandez E; Petry C; Yoneyama K; Kiialainen A; Howard M; Niggli M; Paz-Priel I; Chang T
    Haemophilia; 2021 Nov; 27(6):984-992. PubMed ID: 34480814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emicizumab for the prevention of bleeds in hemophilia A.
    Mahlangu J
    Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
    [No Abstract]   [Full Text] [Related]  

  • 46. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis.
    Hermans C; Ventriglia G; Obaji S; Beckermann BM; Lehle M; Catalani O; d'Oiron R; Frenzel L
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102239. PubMed ID: 38193069
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
    Shima M; Amano K; Ogawa Y; Yoneyama K; Ozaki R; Kobayashi R; Sakaida E; Saito M; Okamura T; Ito T; Hattori N; Higasa S; Suzuki N; Seki Y; Nogami K
    J Thromb Haemost; 2023 Mar; 21(3):534-545. PubMed ID: 36696195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
    Klamroth R; Wojciechowski P; Aballéa S; Diamand F; Hakimi Z; Nazir J; Abad-Franch L; Lethagen S; Santagostino E; Tarantino MD
    J Blood Med; 2021; 12():115-122. PubMed ID: 33664606
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making.
    Mason JA; Young G
    Haemophilia; 2021 Sep; 27(5):724-729. PubMed ID: 34085367
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review.
    Hassan E; Motwani J
    Pediatr Hematol Oncol; 2022 Aug; 39(5):418-426. PubMed ID: 35170384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expert opinion paper on the treatment of hemophilia a with emicizumab.
    López-Jaime FJ; Benítez O; Díaz Jordán BL; Montaño A; Coll J; Quintana París L; Gómez-Del Castillo Solano MDC
    Hematology; 2023 Dec; 28(1):2166334. PubMed ID: 36636993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Successful treatment by switching from activated prothrombin complex concentrate to emicizumab therapy in a hemophilia A patient with inhibitors].
    Sakamoto A; Nakadate H; Watanabe N; Ishiguro A
    Rinsho Ketsueki; 2020; 61(6):617-620. PubMed ID: 32624534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence.
    Kenet G; Fujii T
    Haemophilia; 2024 Mar; 30(2):267-275. PubMed ID: 38291654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.
    McCary I; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Ballester L; Raffini L
    Haemophilia; 2020 Jul; 26(4):631-636. PubMed ID: 32311809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
    Tiede A; Hart C; Knöbl P; Greil R; Oldenburg J; Sachs UJ; Miesbach W; Pfrepper C; Trautmann-Grill K; Holstein K; Pilch J; Möhnle P; Schindler C; Weigt C; Schipp D; May M; Dobbelstein C; Pelzer FJ; Werwitzke S; Klamroth R
    Lancet Haematol; 2023 Nov; 10(11):e913-e921. PubMed ID: 37858328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.
    Peyvandi F; Mahlangu JN; Pipe SW; Hay CRM; Pierce GF; Kuebler P; Kruse-Jarres R; Shima M
    J Thromb Haemost; 2021 Jan; 19 Suppl 1(Suppl 1):32-41. PubMed ID: 33331041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors.
    Hassan E; Jonathan L; Jayashree M
    Haemophilia; 2021 Nov; 27(6):e698-e703. PubMed ID: 34628693
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
    Lee H; Cho H; Han JW; Kim AY; Park S; Lee M; Cho S; Baik D; Kang HY
    Haemophilia; 2021 Jan; 27(1):e12-e21. PubMed ID: 32894895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.